{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:13:07Z","timestamp":1769598787409,"version":"3.49.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2018.00880","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T04:46:04Z","timestamp":1540183564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onset Pompe Disease (LOPD)"],"prefix":"10.3389","volume":"9","author":[{"given":"Daniela","family":"Parisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olimpia","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Mondello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Brizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"Oteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Migliorato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Ciranni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana E.","family":"Mongini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Vita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"key":"B1","first-page":"3389","article-title":"Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency","volume-title":"The Metabolic and Molecular Bases of Inherited Disease.","author":"Hirschhorn","year":"2001"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van","year":"2008","journal-title":"Lancet"},{"key":"B3","first-page":"17","article-title":"Pathophysiological mechanisms in Glycogenosis type II","volume-title":"Advances in Diagnosis and Management of Glycogenosis II","author":"Toscano","year":"2012"},{"key":"B4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","article-title":"Italian GSDII Group Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years","volume":"259","author":"Angelini","year":"2012","journal-title":"J Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13023-016-0442-y","article-title":"Childhood Pompe disease: clinical spectrum and genotype in 31 patients","volume":"11","author":"van Capelle","year":"2016","journal-title":"Orphanet J Rare Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s00415-015-7664-0","article-title":"Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment","volume":"262","author":"Montagnese","year":"2015","journal-title":"J Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: a prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"key":"B8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ymgme.2013.08.005","article-title":"Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies","volume":"110","author":"Preisler","year":"2013","journal-title":"Mol Genet Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1212\/WNL.0000000000002800","article-title":"The genetic basis of undiagnosed muscular dystrophies and myopathies: results from 504 patients","volume":"87","author":"Savarese","year":"2016","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.0042","article-title":"The emerging phenotype of late-onset Pompe disease: a systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol Genet Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ymgme.2011.08.011","article-title":"The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe Registry","volume":"104","author":"Roberts","year":"2011","journal-title":"Mol Genet Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","article-title":"European Pompe consortium european consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience","volume":"24","author":"van","year":"2017","journal-title":"Eur J Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.nmd.2012.09.004","article-title":"Presymptomatic late-onset Pompe disease identified by the dried blood spot test","volume":"23","author":"Wagner","year":"2013","journal-title":"Neuromuscul Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jnnp-2014-310164","article-title":"Italian GSD II group LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population","volume":"87","author":"Musumeci","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2013.03.002","article-title":"Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia","volume":"109","author":"Spada","year":"2013","journal-title":"Mol Genet Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1212\/WNL.0000000000002758","article-title":"Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness","volume":"87","author":"Lukacs","year":"2016","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/2013.jamaneurol.486","article-title":"Diagnosis of Pompe disease: muscle biopsy vs blood-based assays","volume":"70","author":"Vissing","year":"2013","journal-title":"JAMA Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr Neonatol."},{"key":"B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00465559","article-title":"Vacuolated lymphocytes in type II glycogenosis\u2013a diagnostic approach?","volume":"127","author":"von","year":"1977","journal-title":"Eur J Pediatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/jcp.2005.027045","article-title":"Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2500 cases from a single centre","volume":"58","author":"Anderson","year":"2005","journal-title":"J Clin Pathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10545-009-9027-4","article-title":"PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease","volume":"33","author":"Hagemans","year":"2010","journal-title":"J Inherit Metab Dis."},{"key":"B24","first-page":"954","article-title":"Biochemical and ultrastructural study of leucocytes in type II glycogenosis","volume":"83","author":"de","year":"1975","journal-title":"Arch Int Physiol Biochim."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1002\/jcp.26365","article-title":"Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy","volume":"233","author":"Pascarella","year":"2018","journal-title":"J Cell Physiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.2174\/0929867324666170616102112","article-title":"Biomarkers for diagnosing and staging of Fabry disease","volume":"25","author":"Kr\u00e4mer","year":"2018","journal-title":"Curr Med Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/humu.9426","article-title":"Hepatic and neuromuscular forms of glycogenosis type III: nine mutations in AGL","volume":"27","author":"Lucchiari","year":"2006","journal-title":"Hum Mutat."},{"key":"B28","first-page":"261","article-title":"Metabolic myopathies","volume-title":"Inherited Metabolic Diseases","author":"Hoffmann","year":"2002"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2018.00880\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T04:46:07Z","timestamp":1540183567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2018.00880\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":28,"alternative-id":["10.3389\/fneur.2018.00880"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2018.00880","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"article-number":"880"}}